Telix Pharmaceuticals (TLPPF) Stock Price, News & Analysis

Company Overview

Telix Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for cancer imaging and treatment. Its platform combines radioactive isotopes with targeting molecules designed to identify or bind to specific biological markers associated with disease.

The company’s principal commercial product is Illuccix, a gallium-68 PSMA-PET imaging agent used to help detect and manage prostate cancer. Telix is also developing a pipeline of diagnostic and therapeutic radiopharmaceuticals targeting cancers including kidney, brain, and prostate tumors, as well as other medical conditions.

Founded in 2015 and headquartered in Melbourne, Australia, Telix serves healthcare markets across Australia, the United States, Europe, and other international regions through regulatory approvals, commercial partnerships, and distribution arrangements. Christian Behrenbruch is the company’s managing director and group chief executive officer.

Key Stats

• Today's Range: $11.67 to $11.67
• 50-Day Range: $9.49 to $12.55
• 52-Week Range: $5.91 to $13.00
• Volume: N/A
• Average Volume: 4,157 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Buy

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:TLPPF
• CIK: 2007191
• Web: telixpharma.com
• Phone: 61-3-3093-3897
• Fax: N/A
• Employees: 234
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Telix Pharmaceuticals: $20.00
• High Price Target: $20.00
• Low Price Target: $20.00
• Potential Upside/Downside: +71.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A